Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Gastrointestinal and Other Cancers
National Cancer Institute (NCI)
Active, not recruiting ID
For more information, see NCT02968810
This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Questionnaire Administration, Simvastatin, Placebo Administration, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Cirrhosis, Hepatocellular Carcinoma
Marc T Goodman

See list of participating sites